QC Kinetix Advances Regenerative Medicine with 10 Billion Platelet Dosing Standard

Company Adopts New Protocol Across All 176 Clinics to Enhance Non-Surgical Pain Relief

QC Kinetix, the leading regenerative medicine provider in the U.S., is raising the standard for non-surgical joint and chronic pain relief by implementing 10 billion platelet dosing for Platelet-Rich Plasma (PRP) treatments across its 176 clinics nationwide. The initiative, driven by ongoing research and an outcome-based approach, reinforces the company’s commitment to evidence-based medicine to advance PRP therapy and optimize non-surgical pain relief solutions.

Although no universal dosing standards exist for PRP in regenerative medicine, clinical evidence and patient outcome data support the 10 billion platelet dose, which has been shown to enhance treatment outcomes through higher platelet concentrations in PRP therapy. QC Kinetix’s new dosing protocol represents a significant step forward in regenerative medicine.

“Our goal is to provide the most effective, evidence-based regenerative treatments for our patients. Through extensive clinical experience, we’ve determined that a standardized baseline of 10 billion platelets maximizes healing potential, providing the most consistent and effective outcomes,” said Dr. Mitchell Sheinkop, national medical director, QC Kinetix. “Most importantly, it means our patients can get back to doing what they love – whether that’s playing with their grandchildren, returning to sports and hobbies, or simply moving without pain.”

Regenerative medicine has evolved significantly over the past decades, offering new hope for patients suffering from chronic pain. What began with early discoveries in stem cell science and tissue engineering has now transformed into cutting-edge treatments using PRP, mesenchymal stem cells and other biologics to promote healing and reduce inflammation. Progress has steadily advanced as ongoing research continues to refine and expand the potential of regenerative therapies.

"Regenerative medicine is now emerging as a core step in mainstream treatment pathways, offering patients a proactive, minimally invasive solution to traditional pain management," said Dr. Ashley Caravelli, QC Kinetix medical director. "At QC Kinetix, we believe in a regenerative-first approach – one that prioritizes biologic treatments when over-the-counter remedies and physical therapy are not enough but before resorting to surgery. By promoting natural healing, regenerative medicine can delay or even eliminate the need for more aggressive interventions.”

QC Kinetix partners with industry leaders Apex Biologix and EmCyte, known for their advanced PRP processing technology, to provide a comprehensive system that accommodates patients' varying platelet levels. This system is capable of delivering 10 billion or more platelets, with larger systems available for additional joint treatments, ensuring consistent and effective results.

This transition to 10 billion platelets does not alter the overall treatment process for patients. The main difference is the volume of blood drawn, which allows for a more consistent, higher-dose delivery of platelets, leading to better outcomes for patients.

As part of its evidence-based approach, QC Kinetix has implemented advanced tracking methods to evaluate the impact of this standard. Using tools such as DataBiologics and Horiba blood analyzers, the organization is actively gathering data to assess the success of the 10 billion platelet initiative on patient outcomes.

About QC Kinetix

QC Kinetix, headquartered in Charlotte, N.C., is one of the largest providers of regenerative medicine treatments in the United States, promoting an active lifestyle through innovative therapies that address musculoskeletal conditions and joint pain. Its regenerative medicine treatments are specifically designed to relieve chronic and joint pain by maximizing the body's ability to heal and repair itself from the inside out, resulting in vastly improved function and overall quality of life for patients. By leveraging the body’s inherent healing properties, QC Kinetix provides an effective replacement for invasive surgery and addictive pain medications.

With rapid expansion across the U.S., QC Kinetix currently operates 176 corporate and franchise locations in over 100 cities nationwide. For more information, please visit www.qckinetix.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250409289098/en/